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This study was designed to demonstrate the potential of small nanoparticulate lymphotropic 
contrast agents designed to bind with high affinity to lymphoid cells overexpressing the CD45 
antigen. To this end, small gold nanoparticles used as model were conjugated to anti-CD 45 
antibodies and injected in mice in the dorsal toe of the fore/hind paw. Chemical analysis 
demonstrated rapid uptake and transport of the nanoparticles in the lymphatic as well as 
significant retention of the nanoparticles with high binding affinity to lymphoid cells in the 





Accurate staging of cancer is critical to predict overall prognosis as well as to decide on the most 
appropriate treatment(s), and to evaluate the tumour’s response to those treatments. The role of 
lymph node metastasis has been well-demonstrated in the systemic dissemination of cancer, and 
therefore the lymph node status is of vital importance in the staging process [1; 2]. Current 
lymph node staging procedures are based on structural abnormalities (such as size and shape) 
and pathological examination of biopsies, guided or not by imaging-based detection of the 
sentinel lymph node(s) (SLNs). The SLN concept describes the preferential lymphatic metastasis 
of a primary tumour to one or more regional lymph nodes. Identification of the SLNs in current 
clinical practice is performed using dyes for direct intra-operative visualization and radiolabelled 
lymphotropic colloids coupled with nuclear imaging. When injected near the primary tumour, the 
imaging agent is taken up by the adjacent lymphatic and transported to the SLNs. In Australia for 
instance, the clinical lymphotropic radiotracer is 
99m
Tc-antimony trisulfide [3]. For cancers 
where the lymphatic network is well mapped, such as breast cancer, biopsy-based assessment of 
SLN status is commonly used to minimize the burden of lymphadenectomy side-effects and 
associated morbidity. The relevance and utility of the SLN concept in other solid tumours such 
as gastrointestinal cancer has been more controversial with continued debate regarding its role, if 
any, in staging and treatment algorithms [4; 5]. The latter, however, is more the consequence of 
challenges associated with precise lymphatic mapping for such cancers rather than 
pathophysiological considerations. In the context of many deeply-situated cancers, current 
lymphoscintigraphy procedures are severely limited by the inherent low spatial resolution of 
nuclear imaging as well as by the “shine through effect” associated with the close proximity of 
SLNs to the primary tumour [6].  
There is therefore a critical need to develop novel combinations of lymphotropic contrast agents 
and related imaging modalities [7]. Fostered by recent advances in nanotechnology, nanoparticle 
contrast agents are being actively developed and are now entering the clinical arena [8; 9]. In the 
context of lymphatic mapping, a range of novel nanoparticle contrast agents compatible with 
imaging modalities routinely used in the clinical practice have been developed, including iron 
oxide nanocrystals for magnetic resonance imaging [10], high atomic number nanoparticles (e.g. 
gold, bismuth, iodine) for CT imaging [11], nanobubbles and nanoemulsions for ultrasound 
imaging [12; 13], plasmonic nanoparticles for photoaccoustic imaging [14], and quantum dots 
for fluorescence-based imaging [15].  
Although the behaviour of nanoparticle contrast agents within the lymphatics is directly 
correlated to their size and, to a lesser extent, their non-specific affinity for lymphatic tissues, the 
structure-activity relationship remains unclear. A general rule is that small molecules, such as 
those based on blue dyes, diffuse rapidly through the lymphatics and reach the SLNs within 
minutes. On the other hand, larger lymphotropic agents such as antimony-based radiocolloids are 
retained longer in the SLNs, which minimizes the risk of erroneous diagnosis but their slow 
diffusion rate often precludes intraoperative mapping of the SLNs. In an attempt to solve this 
dilemma, small lymphotropic agents designed to bind to macrophages and therefore to be 
retained in the lymph nodes are being developed. The most advanced of these next generation 
lymphotropic agents, Lymphoseek, is a 
99m
Tc labelled dextran-mannose conjugate designed to 
have increased retention in the SLNs [16; 17]. Two Phase 3 multi-centre clinical trials have been 
completed and the U.S. Food and Drug Administration (FDA) has recently accepted a New Drug 
Application for this radiopharmaceutical. Although such agents are typically associated with 
faster clearance from the injection site when compared to relatively large colloid-based agents, 
which could aid in reducing the “shine-through effect”, they remain intrinsically limited by the 
poor spatial resolution of nuclear imaging. In addition, the very rapid transport of such agents to 
the SLNs makes it challenging to accurately image lymphatic drainage.  
Based on the previous findings, we hypothesize here that nanoparticle contrast agents in the 10-
30 nm size range with high binding affinity for lymphoid cells are ideal imaging agents of the 
SLNs. On one hand, their dynamic transport in the lymphatics can be readily controlled by 
tuning their hydrodynamic size. On the other hand, their binding affinity and consequently their 
retention in the lymph nodes can be controlled through bioconjugation with biologically active 
ligands. Molecularly targeted (herein collectively referred to as ‘immunotargeted’) nanoparticles 
are being actively developed towards increasing their therapeutic index and diagnostic utility [8; 
18]. A recent study illustrated the potential of such agents using mannose-conjugated gold 
nanoparticles, which were found to accumulate in the popliteal lymph nodes after injection in 
rat’s footpads [19].   
The aim of this work was to investigate the lymphatic transport of small solid nanoparticles with 
high affinity for CD45 expressing cells. CD45 is a transmembrane glycoprotein of the leukocyte-
specific receptor-like protein tyrosine phosphatase expressed at high density on nucleated 
haematopoietic cells. It is therefore a good molecular target candidate for delivery to lymphoid 
cells. 18 nm gold nanoparticles used here as a model for solid nanoparticle lymphotropic agents 
were conjugated with an anti-CD45 antibody, and their properties were characterized in vitro and 
in vivo. A critical requirement in the experimental design was avoiding aggregation during the 
bioconjugation procedure. This was achieved using a polymeric coating based on polyethylene 
glycol molecules (PEG) with different molecular weights designed to maximized bioconjugation 
yield while maintaining the colloidal stability of the nanoparticles. As a result of the high binding 
affinity to CD45+ lymphoid cells, immunotargeted nanoparticles were retained in the popliteal 
and axillary lymph nodes after interstitial injection in mouse fore/hind paw while their non-
conjugated counterparts were cleared from the lymphatics rapidly. 
 
2. Materials and Methods 
2.1. Materials 
Chloroauric acid (HAuCl4·3H2O), sodium citrate, N-hydroxysuccinimide (NHS), N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), Phosphate Buffered Saline 
(PBS), and a silver enhancer kit were obtained from Sigma-Aldrich and used as received from 
the manufacturer without further purification. Water used in the experiments was purified with a 
Millipore water treatment system (organic content less than 5 ppb). Polyethylene glycol thiol 
(HS-PEG-COOH) with an average molecular weight of 5000 g/mol was purchased from Rapp 
polymer Gmbh. Short chain length PEG thiol acid (molecular weight 458.6) were purchased 
from Polypure. Mouse CD 45 (Ptprc monoclonal antibody) was purchased from Abnova.  
 
2.2. Synthesis and Biofunctionalization of the Lymphotropic Agents 
Gold nanoparticle synthesis and surface modification with PEG have been carried with minor 
modification from our previous study [20]. Briefly, citrate coated gold nanoparticles were 
prepared using the standard citrate method. Mixed thiolated PEG molecules comprising 
carboxylic functionalized short chain length PEG molecules (Fw 458.6) and PEG with longer 
chain length (Fw 5000) were used to stabilize the gold nanoparticles and enable optimal 
bioconjugation of monoclonal antibodies to the nanoparticles. The mixture of PEGs were 
prepared at a concentration of 1 mg/mL and mixed with a ratio of 4:1 (Fw 5000: Fw 458.6). The 
mixed PEG solution was added to the gold nanoparticle solution under vortex and left to react for 
at least 6 hours at room temperature. After purification by centrifugation, the carboxyl groups on 
the PEGylated gold nanoparticles (1.0 mM, 1 mL) were activated using NHS (20 mg/mL) and 
EDC (15 mg/mL) for 5 min. The nanoparticle suspensions were then quickly centrifuged and 
resuspended into PBS (900 µL). Mouse anti-CD 45 antibody (0.5 mg/mL, 0.1 mL) was added 
rapidly to the activated gold nanoparticles and left to react at room temperature and stored at 
4 
o
C after reaction. The antibody-conjugated nanoparticles were washed with PBS twice at 4 
o
C 
prior to use. 
The physicochemical properties of the nanoparticles before and after the bioconjugation were 
determined using UV-Vis absorption and dynamic light scattering. UV-Vis spectra were 
determined using a Varian Cary 5 UV-Vis-NIR spectrophotometer at room temperature. The 
hydrodynamic diameter of gold nanoparticles was measured via dynamic light scattering using a 
Zetasizer Nano ZS equipped with a 633nm He-Ne laser (Malvern Instruments). The morphology 
and size distribution of gold nanoparticles prepared on a copper grid were analysed using a 
Philips CM100 transmission electron microscope (TEM).  
 
2.3. Binding Affinity of the Anti-CD45 Bioconjugated Nanoparticles to Macrophages 
To determine the active targeting effect of the immuno-functionalized gold nanoparticles, an in 
vitro assay was designed using RAW 264.7 macrophages used here as a model for lymphatic 
cells. RAW 264.7 macrophage cells were cultured in complete media consisting of Dulbecco's 
Modified Eagle's Medium supplemented with 10% (v/v) fetal bovine serum (FBS) in a 
humidified incubator at 37 ºC, 5% CO2, and 100% humidity. A custom-made silicone well 
chamber device was cleaned and mounted on a clean glass coverslip. The glass surface was 
treated with poly-L-lysine (1 mg/mL) before seeding the cells. Cells were plated into the wells at 
densities of 10,000-cells per well. After 24 h cell culture, the cells were incubated for 2 h at 
37 °C with gold nanoparticles (0.01 mM and 0.04 mM Au concentration) conjugated or not with 
anti-CD45 antibody. Cells were then extensively washed in PBS and fixed in cold methanol at -
20 °C. Triplicate samples were performed for each analysis and each test was repeated three 
times. 
To enable microscopic visualization of cellular binding, gold nanoparticles were enlarged using 
standard silver-enhancement, washed thoroughly, and mounted in a mounting media for 
observation. The cellular binding of the targeted and non-targeted nanoparticles was visualized 
using a Nikon inverted light microscope operating in bright field under high magnification (100× 
objective, oil-immersion bright field condensers). The percentage of cells positive for gold 
nanoparticle binding (the number of gold nanoparticle targeted cells vs. total cells in the image) 
was determined by manual cell counting. The bright field microscopy study was complemented 
with reflectance confocal microscopy (LSM510) which provided higher imaging quality and 
increased sensitivity to the presence of the gold nanoparticles. In reflectance confocal 
microscopy, the high light scattering associated with plasmonic nanoparticles enable 
observations at the single nanoparticles level [21; 22]. To determine the three dimensional 
intracellular locations of the total NPs, vertical spatial images of nanoparticles within the RAW 
cells were generated by z-scans in 0.25 μm steps. The z-stack images were overlaid for each 
sample to confirm the targeting ability of different functionalized gold nanoparticles to cells. 
 
2.4. Lymphatic Transport and Retention of the anti-CD45 Nanoparticles 
BALB/cByJNarl mice (5–7 weeks old) were purchased from National Laboratory Animal Center 
(NLAC) in Taiwan and all procedures involving animals were approved by Academia Sinica 
Institutional Animal Care and Utilization Committee (ASIACUC). BALB/cByJNarl mice were 
anesthetized with isofluorane and injected subcutaneously in the dorsal toe of the fore/hind paw 
with PEGylated gold nanoparticles and anti-CD45 gold nanoparticles (9 mice per group) at a 
gold dose of 1 mg/kg body weight (Au concentration of 1 mg/mL). Mice were euthanized 2, 6 
and 24 h post-administration of the gold nanoparticles. The axillary and popliteal lymph nodes 
were collected, cleaned and weighed for the lymphatic distribution of the particles with different 
surface functionalization. For ICP-MS analysis, the lymph nodes with the gold nanoparticles 
were dissolved by aqua regia (the volume ratio of 37% HCl and 70% HNO3 was 3:1). The total 
amount of gold in harvested lymph nodes after nanoparticle treatment was quantified by ICP-MS 
(ICP-MS 7500 CS, Agilent Technologies, USA).  
 
3. Results and discussion 
3.1. Design of the Bioconjugated Contrast Agents 
Gold nanoparticles were chosen here as a model nanoparticle contrast agent owing to the 
existence of well-established synthesis routes with excellent control of the particle size as well as 
their unique optical properties [23]. Nanoparticles with an average diameter of 18 nm were 
synthesized and the size was confirmed by TEM measurement (Figure 2. A). Previous studies 
have shown that nanoparticles within this size-range transport rapidly in the lymphatics [24; 25; 
26], making them ideal for this study.  
PEGylated gold nanoparticles were engineered with an optimized coating procedure designed to 
prevent aggregation of the nanoparticles while enabling high conjugation yields with biological 
ligands. The terminal carboxylic acids of PEG molecules on the gold nanoparticles were 
conjugated to anti-CD45 antibodies via carbodiimide chemistry. The colloidal stability of the as-
synthesized gold nanoparticles and the functionalized gold nanoparticles was established by 
dynamic light scattering and UV-Vis measurements. The hydrodynamic radius increased by 
15 nm after bioconjugation with anti-CD45 antibodies, which confirmed the successful surface 
modification of nanoparticles (Figure 2. B). The monomodal distribution of the gold 
nanoparticles before and after bioconjugation showed that particles were well dispersed and 
aggregation-free. The latter was confirmed by UV-Vis absorption, where no broadening of the 
plasmon bands could be observed for bioconjugated nanoparticles (Figure 2. C). Nanoparticles 
are prone to aggregation during bioconjugation with biological ligands and it is critical to 
determine the hydrodynamic size distribution of bioconjugated nanoparticles prior to their 
application in biological systems [27; 28]. In the present study, aggregation would have 
drastically influenced the lymphatic transport of the nanoparticles and in turn have prevented 
meaningful comparison between the bioconjugated and non-conjugated contrast agents.  
 
3.2. In vitro Binding Affinity of the anti-CD45 Nanoparticles to Lymphatic Cells 
To compare the in vitro cellular binding of the nanoparticles targeted or not to CD45+ cells, 
these two groups of nanoparticles were incubated with macrophages for 2 h at a relatively low 
concentration of gold nanoparticles (0.01 mM and 0.04 mM) chossen to avoid binding-saturation. 
The murine RAW 264.7 macrophage cell line was selected as an in vitro model of lymphoid 
cells. Taking advantage of the high Rayleigh scattering of gold nanoparticles after silver 
enhancement, light microscopy was used to determine the percentages of RAW 264.7 cells 
displaying unambiguous positive labelling with the nanoparticles. As shown in Figure 3, anti-
CD45 conjugated nanoparticles had a high binding affinity to the macrophages as demonstrated 
by the fact that all tested cells were successfully targeted by the nanoparticles. On the other hand, 
only minimal binding was observed for the non-targeted nanoparticles as less than 10% of the 
cells showed unambiguous staining by the nanoparticles (Figure 3. C). To obtain further insight 
into the cell-nanoparticle interactions, the cells were imaged by confocal microscopy in the 
reflectance mode. Scattering of incident light dominates over plasmon absorption for plasmonic 
nanoparticles larger than approximately 40 nm, which enable their visualization at the single 
nanoparticle level in the reflectance mode [21; 22; 29]. Figure 4 shows the phase contrast and 
reflectance images for the RAW cells after incubation with the nanoparticles for 2 hours and 
silver enhancement which was used to accentuate the scattering of the small nanoparticles used 
in this study. In order to represent the total amount of nanoparticles bound to or internalized 
inside the RAW 264.7 macrophages, z-stack data was overlaid to obtain an accurate rendering of 
nanoparticle-cell interactions. In agreement with previous reports, reflectance confocal imaging 
provided significantly increased sensitivity to the presence of the scattering nanoparticles in 
comparison to bright field and dark field microscopy. Reflectance data confirmed the bright field 
microscopy observations that the anti-CD45 conjugated nanoparticles have a very high binding 
affinity to the RAW 264.7 cells as shown by the very high staining rate observed after two hours 
(Figure 4. A-C). In contrast, negligible uptake of non-targeted PEGylated nanoparticles by the 
macrophages was observed in the confocal microscopic images (Figure 4. D-F). Even at very 
low concentration, the anti-CD45 targeted nanoparticles were taken up avidly by the 
macrophages (Figure 4. G-I). The presence of larger and bright structures in the reflectance 
images could be associated with endocytotic internalization of the nanoparticles after binding to 
the macrophages [30]. These in vitro studies confirmed that the PEG coating drastically inhibited 
non-specific binding to macrophages while enabling efficient bioconjugation with biological 
ligands. The protective effect against phagocytosis of PEG-based nanoparticles coating 
originates in reduction of protein fouling and is strongly dependant on the properties of the 
polymeric adlayers [31].  
 
3.3. Lymphatic Drainage and Retention in Mice 
To investigate the lymphatic drainage of the nanoparticles conjugated or not with the anti-CD45 
antibodies, BALB/cByJNarl mice were injected subcutaneously in the dorsal toe of the fore/hind 
paw (1 mg Au / kg body weight). At various time points, the animals were sacrificed and the 
axillary and popliteal lymph nodes were collected and analysed using ICP-MS to determine the 
gold concentration. Although the drainage distribution varies between individual mice, the 
injection through the hind pad typically drains to the popliteal (then on to iliac) [32]. The axillary 
lymph node serves as the first lymph node to receive the drainage from the fore pad.  
Accumulation of the gold nanoparticles within the nodes could be readily visualized from the 
reddish colourization of the nodes (Figure 5.), which greatly facilitated the localization of the 
otherwise transparent nodes. Stronger colourization was typically observed for explanted lymph 
nodes in the anti-CD45 groups in comparison to the nodes from animals injected with non-
targeted nanoparticles (Figure 5. B and C).  The improved in vivo uptake and retention of the 
anti-CD45 nanoparticles was confirmed using ICP-MS. The time points chosen to quantify the 
dynamic lymphatic drainage were 2, 6, and 24 h post-injection (Figure 6.). At 2 h post injection, 
similar concentrations of gold were found in nodes for both the anti-CD45 targeted group and the 
non-targeted control (128 ng vs. 103 ng means for the anti-CD45 nanoparticles and control 
respectively, p>0.05). This result demonstrates that both nanoparticle preparations were rapidly 
transported to the lymph nodes, in agreement with previous reports on the lymphatic uptake of 
nanoparticles in this size range [24; 25; 26]. The amount of gold in the lymph nodes was 
however significantly higher for subsequent time-points for animals administrated with anti-
CD45 conjugated nanoparticles in comparison to the non-conjugated controls. Whilst the gold 
concentrations within the popliteal and axillary nodes fell below the limit of detection of the 
ICPMS at 6 and 24 hours for the control group, gold concentrations in the anti-CD45 targeted 
group increased after the 2 h time point. The peak accumulation time point for the popliteal 
lymph nodes was at 6 h (570 ng, 2.9 % ID at 6 h vs. 327 ng, 1.6 % at 24 h), whilst the amount of 
the immunotargeted nanoparticles continued to increase after 6 h until 24 h for axillary lymph 
nodes (182 ng, 0.9 % ID at 6 h vs. 470 ng, 2.4 % at 24 h). The ICPMS data demonstrates that the 
anti-CD45 conjugated nanoparticles were retained in the lymph nodes, most likely due to 
specific binding to CD45+ lymphoid cells which highly express the CD45 antigen. On the 
contrary, PEGylated controls were quickly cleared from the lymph nodes (within 6) and hence 
they had a much shorter retention time in the lymph nodes. These results can be compared 
qualitatively to those reported with Lymphoseek and other mannose-targeted lymphotropic 
agents. In a recent clinical study, the mean sentinel lymph node retention for Lymphoseek was 
1.5±1.7% [33]. Similarly, 1.32 % of gold nanoparticles conjugated with mannose were retained 
in the popliteal nodes after injection in Wistar rats [19]. Although further studies are required, 
these data suggest that lymphotropic nanoparticulate contrast agents designed to bind with high 
affinity to lymphoid cells which intrinsically overexpress the CD45 antigen is a promising 
alternative to mannose-based targeting approaches. The high node retention observed in this 
study with anti-CD45 targeted nanoparticles was consistent to that obtained using anti-CD4 
conjugated nanoparticles [28]. However, large aggregates (up to 500 nm) were found after the 
antibody conjugation in these studies and the size variation upon bioconjugation make it difficult 
to draw conclusions on transport via the lymphatic drainage [27; 28]. To unravel the complex 
lymphatic behaviour of exogenous contrast agents, it is critical to fully characterize their 
physicochemical properties and control their interactions with biological components. The latter 
was achieved here by using mixed PEG coatings which enabled efficient bioconjugation with 
monoclonal antibodies while providing excellent colloidal stability during the conjugation 
process and in biological environments. In addition to their protective effect against nanoparticle 
aggregation, PEG-based nanoparticle coatings were found to drastically increase the lymphatic 
drainage of phospholipid liposomes [34]. The specific effect of the PEG coating could not be 
tested here, since nanoparticles without PEG coating rapidly aggregated during the conjugation 
as well as in biological environments, which precluded meaningful investigation of the chemistry 
versus size effects on nanoparticle lymphatic transport.  
 
4. Conclusions 
The metastatic status of regional lymph nodes is the most significant prognostic factor in breast 
cancer, melanoma and other solid tumors with lymphatic spread. Clinical application of the 
Sentinel Lymph Node concept remains limited in a number of diseases due to the limitations of 
the current lymphotropic tracers used to identify lymphatic drainage from the primary tumor. 
This study aimed to demonstrate the potential of lymphotropic nanoparticle contrast agents 
designed to bind with high affinity to lymphoid cells overexpressing the CD45 antigen. To this 
end, gold nanoparticles with a 18 nm diameter were prepared and bioconjugated with anti-CD45 
antibodies through an optimized polyethylene glycol (PEG) coating designed to protect the 
nanoparticles from aggregation. Using a murine macrophage cell line as a model, the high 
binding affinity for lymphoid cells of the anti-CD45 nanoparticles was demonstrated in vitro. In 
contrast, unconjugated nanoparticles showed minimal non-specific binding to the macrophage 
thanks to the dense PEG coating. Chemical analysis of the popliteal and axillary lymph nodes of 
mice was conducted at different time points after subcutaneous injection of the nanoparticles in 
the dorsal toe of the fore/hind paw. This study confirmed the rapid lymphatic uptake and 
transport of the small nanoparticles. At 6 and 24 hours, the anti-CD45 targeted nanoparticles 
were significantly retained in the nodes and compared favourably with lymphatic tracers 
targeting mannose receptors. The combination of small hydrodynamic size, optimal PEG coating 
and high binding affinity to CD45 positive lymphoid cells appears to be suitable for the 
development of advanced detection agents for the SLNs. Building on this study and the 
availability of advanced nanoparticulates contrast agents compatible with state-of-the-art 
imaging modalities such as magnetic resonance imaging, we expect that improved imaging 
procedures for pre- and intra-operative detection of the SLNs can be developed.   
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Figure 1. Schematic illustration of lymphatic drainage/retention of lymphotropic nanoparticulate 
tracers from the primary tumor in SLN imaging. Small nanoparticles are rapidly uptake and 
transported through the lymphatic and transit through the lymph nodes. Nanoparticles with high 
binding affinity with CD45 expressing lymphoid cells are retained in the nodes while non-







Figure 2. Characterization of gold nanoprobes. (A) A TEM image of the as-synthesized NPs; (B) 
UV-visible absorption of the as-synthesized, PEGylated, and anti-CD45 conjugated gold 
nanoparticles; (C) Hydrodynamic particle sizes of the as-synthesized and anti-CD45 conjugated 













Figure 3. Bright field microscopic images of nanoparticles associated with RAW cells. (A) Anti-
CD45 conjugated gold nanoparticles; (B) PEGylated gold nanoparticles; (C) Percentage of cells 
associated with anti-CD45 conjugated gold nanoparticles and PEGylated gold nanoparticles from 





Figure 4. Confocal microscopic images (bright field, reflectance and their overlay) of 
nanoparticles binding to RAW cells. (A-C) Anti-CD45 conjugated gold nanoparticles at a gold 
concentration of 0.04 mM; (D-F) PEGylated gold nanoparticles at a gold concentration of 
0.04 mM; (G-I) Anti-CD45 conjugated gold nanoparticles at a gold concentration of 0.01 mM; 






          
Figure 5. Photographs showing nanoparticles. (A) Accumulation in the popliteal lymph node in a 
mouse before dissection 24 h post-injection; (B) Accumulation in the axillary lymph node 














Figure 6. ICP-MS quantitative data of gold in (A) popliteal lymph nodes (B) axillary lymph 
nodes, comparing anti-CD45 conjugated gold nanoparticles and PEGylated gold nanoparticles at 
different time points post-injection. 
 
 
 
 
